Reductions in locomotor activity following central opioid receptor subtype antagonists in rats

Physiology and Behavior

Volumn 60, Issue 3, 1996, Pages 833-836

  Leventhal, Liza ^a   Cole, Jessica L ^a   Bodnar, Richard J ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Delta1 receptor; Delta2 receptor; Kappa1 receptor; Locomotor activity; Mu receptor; Mu1 receptor; Opioids

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE, 5 DEXTRO LEUCINE, 6 CYSTEINE]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONAZINE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; HYPERACTIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; WEIGHT REDUCTION;

EID: 0030249017     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(96)00103-5     Document Type: Article

References (35)

1. 1. Adams, P. M.; Beauchamp, R.; Alston, C. Potentiation of apomorphine and d-amphetamine effects by naloxone. Life Sci. 28:629-634; 1981.
2. 2. Andrews, J. S.; Holtzman, S. G. Effects of naloxone and diprenorphine on amphetamine-stimulated behavior in guinea-pigs and rats. Neuropharmacology 26:1115-1120; 1987.
3. 3. Arjune, D.; Bodnar, R. J. Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphamine. Brain Res. 534:313-316; 1990.
4. 6]-enkephalin (DALCE), a short-acting agonist and long-acting antagonist at the delta opioid receptor. Pharmacol. Biochem. Behav. 39:429-436; 1991.
5. 5. Arjune, D.; Standifer, K. M.; Pasternak, G. W.; Bodnar, R. J. Reduction by central beta-funaltrexamine of food intake in rats under freely feeding, deprivation and glucoprivic conditions. Brain Res. 535:101-109; 1990.
6. 6. Bodnar, R. J. Opioid receptor subtype antagonists and ingestion. In: Cooper, S. J.; Clifton, P. J., eds. Drug receptor subtypes and ingestive behaviour. London: Academic Press; 1996:127-146.
7. 7. Brady, L. S.; Holtzman, S. J. Effects of intraventricular morphine and enkephalins on locomotor activity in nondependent, morphine-dependent and postdependent rats. J. Pharmacol. Exp. Ther. 218:613-620; 1981.
8. 8. Cole, J. L.; Leventhal, L.; Pasternak, G. W.; Bowen, W. D.; Bodnar, R. J. Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats. Brain Res. 678:168-176; 1995.
9. 9. Dettmar, P. W.; Cowan, A.; Walter, D. S. Naloxone antagonizes behavioural effects of d-amphetamtne in mice and rats. Neuropharmacology 17:1041-1044; 1978.
10. 10. Havemann, U.; Kuschinsky, K. Locomotor activity of rats after injection of various opioids into the nucleus accumbens and septum mediale. Naunyn Schmiedebergs Arch. Pharmacol. 331:175-180; 1985.
11. 11. Hecht, A.; Schiorring, E. Behaviour effects of low and high acute doses of morphine in solitary mice. Psychopharmacology 64:73-81; 1979.
12. 12. Hitzemann, R.; Curell, J.; Hom, D.; Loh, H. Effects of naloxone on d-amphetamine-and apomorphine-induced behavior. Neuropharmacology 21:1005-1011; 1982.
13. 13. Hooks, M. S.; Jones, D. N. C.; Justice, J. B.; Holtzman, S. G. Naloxone reduces amphetamine-induced stimulation of locomotor activity and in vivo dopamine release in the striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 42:765-770; 1992.
14. 14. Horan, P.; Taylor, J.; Yamamura, H. I.; Porreca, F. Extremely long-lasting antagonistic actions of nor-binaltorphamine (nor-BNI) in the mouse tail-flick test. J. Pharmacol. Exp. Ther. 260:1237-1243; 1992.
15. 15. Iwamoto, E. T. Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: Influence of dopaminergic agonists and antagonists. J. Pharmacol. Exp. Ther. 217:451-460; 1981.
16. 16. Iwamoto, E. T. An assessment of the spontaneous activity of rats administered morphine, phencyclidine, or nicotine using automated and observational methods. Psychopharmacology (Berlin) 84:374-378; 1984.
17. 17. Jones, D. N. C.; Bowen, W. D.; Portoghese, P. S.; Holtzman, S. G. Delta-opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine. Eur. J. Pharmacol. 249:167-177; 1993.
18. 18. Jones, D. N. C.; Holtzman, S. G. Long-term kappa-opioid receptor blockade following nor-binaltorphamine. Eur. J. Pharmacol. 215:345-348; 1992.
19. 19. Kozak, W.; Conn, C. A.; Kluger, M. J. Body temperature, motor activity and feeding behavior of mice treated with beta-chlornaltrexamine. Physiol. Behav. 58:353-362; 1995.
20. 20. Levine, A. S.; Morley, J. E.; Gosnell, B. A.; Billington, C. J.; Bartness, T. J. Opioids and consummatory behavior. Brain Res. Bull. 14:663-672; 1985.
21. 21. Mann, P. E.; Pasternak, G. W.; Hahn, E. F.; Curreri, G.; Lubin, E.; Bodnar, R. J. Comparison of chronic naloxone and naloxonazine effects upon food intake and body weight maintainance in rats. Neuropharmacology 27:349-355; 1988.
22. 22. Meyer, M. E.; McLaurin, B. I.; Allen, M.; Meyer, M. E. Biphasic effects of intraaccumbens mu-opioid peptide agonist DAMGO on locomotor activities. Pharmacol. Biochem. Behav. 47:827-831; 1994.
23. 2), a potent mu-opioid peptide agonist, affects various patterns of locomotor activities. Pharmacol. Biochem. Behav. 51:149-151; 1994.
24. 1-opioid agonist, pCl-DPDPE, differentially affects patterns of locomotor activity. Pharmacol. Biochem. Behav. 51:359-362; 1995.
25. 25. Meyer, M. E.; Meyer, M. E. Behavioral effects of mu opioid agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol. Biochem. Behav. 46:391-395; 1993.
26. 26. Meyer, M. E.; Meyer, M. E. Behavioral effects of opioid receptor agonists, DAGO, DPDPE and DAKLI on locomotor activities. Pharmacol. Biochem. Behav. 45:315-320; 1993.
27. 27. Michael-Titus, A.; Dourmap, N.; Constentin, J. Mu and delta opioid receptors control differently the horizontal and vertical components of locomotor activity in mice. Neuropeptides 13:235-242; 1989.
28. 28. Morley, J. E.; Levine, A. S.; Yim, G. K. W.; Lowy, M. T. Opioid modulation of appetite. Neurosci. Biobehav. Rev. 7:281-305; 1983.
29. 29. Paronis, C. A.; Waddell, A. B.; Holtzman, S. G. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphamine. Pharmacol. Biochem. Behav. 46:813-817; 1993.
30. 30. Schnur, P.; Hang, D. Naloxone reversal of morphine elicited hyperactivity. Life Sci. 40:329-333; 1987.
31. 31. Simone, D. A.; Bodnar, R. J.; Goldman, E. J.; Pasternak, G. W. Involvement of opioid receptor subtypes in rat feeding behavior. Life Sci. 36:829-833; 1985.
32. 32. Spanagel, R.; Almeida, O. F. X.; Shippenberg, T. S. Evidence that nor-binaltorphamine can function as an antagonist at multiple opioid receptor subtypes. Eur. J. Pharmacol. 264:157-162; 1994.
33. 33. Swerdlow, N. R.; Amalric, M.; Koob, G. F. Nucleus accumbens opiate-dopamine interactions and locomotor activation in the rat: Evidence for a presynaptic locus. Pharmacol. Biochem. Behav. 26:765-769; 1987.
34. 5)-enkephalinamide and morphine on locomotor activity in mice. Psychopharmacology (Berlin) 72:299-301; 1980.
35. 35. Ukai, M.; Holtzman, S. G. Effects of beta-funaltrexamine on ingestive behaviors in the rat. Eur. J. Pharmacol. 153:161-165; 1988.